OrthoPediatrics Q2 revenue rises 15%, beats estimates

OrthoPediatrics said second-quarter revenue growth was primarily driven by global Trauma & Deformity and OPSB product sales, with multiple product lines contributing.

The company attributed international revenue growth to increased procedure volumes and limited set sales.

It said scoliosis revenue fell due to lower 7D Technology sales and fewer international set sales, partially offset by higher Response fusion revenue and Verteglide addition.

The current average analyst rating on the shares is "buy", with 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" recommendations.

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy".

Wall Street's median 12-month price target for OrthoPediatrics Corp is $24.00, about 15% above its August 3 closing price of $20.87.